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EPIGRAPH
Patience and tenacity ofpurpose are worth more than twice their weight of
cleverness.
Thomas Henry Huxley, English Biologist
x
ABSTRACT
In this study, the effect of heparin on three extracellular matrix
glycoproteins in porcine aortic endothelial cells was examined. For the
extracellular matrix glycoproteins, fibronectin, thrombospondin, and laminin, a
concentration range of heparin was applied to endothelial cells and then a variety
of biochemical techniques were run to determine that a change in both newly
synthesized and expressed protein levels was occurring. In addition, the effect of
heparin on cell adhesion molecules was also studied. The results obtained for
fibronectin and thrombospondin were compared to results published in the
literature on human umbilical vein endothelial cells grown in the presence of
growth factors and appeared to be similar. Since there is no published
information on heparin's affect of laminin, cycloheximide was also be applied to
show that blocking protein synthesis did have an effect on laminin protein levels.
Finally, the data that was obtained here may eventually provide important clues to
improvin~ the treatment of vessel wall injury in diseased states.
INTRODUCTION
Cardiovascular disease still remains one of the leading causes of mortality
in the United States and Western Europe. Atherosclerosis, the principal cause of
myocardial and cerebral infarction, accounts for the majority of the deaths (Ross,
1993b).
Atherosclerosis is characterized by large intracellular lipid accumulations,
endothelial cell damage, extensive vascular smooth muscle cell proliferation and
changes in the glycosaminoglycan composition of the affected vessel walls
(Hyslop et. aI., 1993).
In the 1970's, Ross and colleagues proposed the 'response-to-injury'
hypothesis of atherogenesis. Initially it was believed that any form of injury,
whether it be physical, viral, or chemical injury to the endothelial cell lead to
platelet adherence to the arterial wall and resulted in the atherosclerotic plaque.
Today, more recent versions have stressed the role oflocal cell-derived factors
that are provoked by vascular injury (Dicorleto, 1993).
Since the endothelial cell lies positioned between the circulating blood
and vascular smooth muscle cells, endothelial cell injury or activation may 1)
alter permeability properties 2) express binding sites for monocyte activators 3)
secrete oxygen free radicals that can modify nearby low density lipoprotein (LDL)
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or directly damage neighboring cells and finally 4) synthesize and secrete PDGF
mitogens and/or chemoattractants for medial smooth muscle cells (Dicorleto,
1993).
However, in healthy endothelium, endothelial cells produce heparan
sulfate proteoglycans which are heparin like molecules as well as other molecules
with antiproliferative properties and may explain why platelets and monocytes
usually do not adhere at the blood vessel wall and why vascular smooth muscle
cells neither migrate nor proliferate (Shulman, 1990).
Therefore, exogenous heparin may aid in this function. Heparin, a known
anticoagulant and highly anionic molecule has been discussed as a treatment for
atherosclerosis. When healthy endothelium is injured, it loses its normal negative
electrical charge. Heparin provided by injection restores this protective
negativity. Heparin also inhibits the platelet derived growth factor from
promoting the over-growth of medial smooth muscle cells which contribute to
plaque formation. Therefore, treatment with low doses of heparin administered
intravenously, subcutaneously, orally, or by inhalation at regular intervals is able
to reduce or reverse atherosclerotic effects (Hyslop, et. aI., 1993).
On the other hand, because of other serious complications of heparin
treatment such as osteoporosis and internal bleeding, heparin's effect on the
endothelial cell and surrounding environments warrants further study.
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Chapter 1
STATEMENT OF THE PROBLEM
1
The originating event in the progression of atherosclerosis is the injury to
the endothelium (Harrison, 1992, and DiCorleto, 1993). For this to occur,
monocytes must attach to the endothelium (Davies, et. al., 1993). Cell-adhesion
molecules are involved in this interaction. In addition, an important part of the
regulation of the endothelial cell behavior is played by adhesive glycoproteins
found in the extracellular matrix. These proteins serve specific functions such as
controlling the attachment, migration, and synthetic activity of the cells (Ditto, et.
al., 1991). During atherosclerosis, several aspects of the cell-matrix interactions
as well as cell-cell interactions may be disturbed. However, since heparin has
been shown to inhibit several aspects of atherosclerosis, it is important to study
the interaction of heparin, endothelial cells, the extracellular matrix, and cell-
adhesive molecules in the prevention and treatment ofvascular disease.
4
The objectives of the project were:
1. To study the effect of heparin on cell-adhesion protein levels in
porcine aortic endothelial cells.
2. Determine if there were any changes in extracellular matrix protein
expression levels of laminin, fibronectin, and thrombospondin as a
result of the addition of heparin.
3. Compare my results on porcine aortic endothelial cells grown without
the addition of growth factors to results published in the literature on
human umbilical vein endothelial cells grown in the presence of
endothelial cell growth factor for Fibronectin and Thrombospondin.
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Chapter 2
Literature Review
Extracellular Matrix
The major components of the extracellular matrix are collagens,
proteoglycans, and adhesive glycoproteins. Collagens are usually the main
organic constituents of the connective tissue matrix and are responsible for the
strength and form of tissues. Proteoglycans play an important role in tissue
resilience and filtering. Some proteoglycans have a capacity to specifically bind
other matrix molecules and growth factors while others act as matrix receptors on
the surface. An important part of regulation of the cell behavior is played by
adhesive glycoproteins belonging to the fibronectin and laminin families (Ditto,
et. aI., 1991).
Basement membranes are specialized types of extracellular matrices laid
down by epithelial cells and endothelial cells. They are composed of a complex
and tissue specific mixture of glycoproteins and proteoglycans usually organized
into the two layers ofbasement membrane, lamina lucida and lamina densa.
Basement membranes are always found between endothelial cells and connective
tissue where they act as a selective barrier, restricting the passage of cells and
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molecules betWeen the tissue compartments. Other functions ofbasement
membranes include anchorage of the basal endothelial cells, morphogenesis,
tissue differentiation and regeneration (Ditto, et. aI., 1991).
Proteoglycans are a large group of extracellular and cell-surface
macromolecules that function in regulating cell adhesion, growth, and
extracellular matrix formation (Jackson, et. aI., 1991). They are composed of a
protein core in which serine-glycine sequences. serve as attachment sites for one
or more glycosaminoglycan chains. Heparan sulfate proteoglycans contain
heparan sulfate. In addition to the function in cell adhesion and matrix binding,
heparan sulfate proteoglycans regulate cellular growth, lipid metabolism, and
basement membrane function (Jackson, et. aI., 1991)
Basement membranes contain large heparan sulfate proteoglycans that
consist of a core protein of400 kDa and three to fpur heparan sulfate chains that
are clustered at one end of the molecule. These proteoglycans occur in close
association with and are probably bound to other matrix macromolecules such as
laminin and fibronectin (Heremans, et. aI., 1990).
All tissues have glycoproteins, the major function of which is to bind cells
to the extracellular elements. The major adhesive glycoproteins of the
endothelial extracellular matrix are laminin, fibronectin, and thrombospondin. In
the basement membrane, laminin serves as the major adhesive glycoprotein.
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Laminins are glycoproteins of about 850,000 molecular weight composed of three
polypeptides chains called A, B1, and B2, that are organized in a crosslike
manner. This structural arrangement has three short arms, each with two globular
domains and a long arm that ends with a large globular domain. The three chains
intersect at the center of the cross, are linked by disulfide bonds and then run
together, in parallel to form the rodlike segment of the long arm. The Bl and B2
chains terminate at the end of the rod and are linked together in this region by a
single disulfide bond. The carboxyl terminus ofthe A chain forms the large
globule at the end of the long arm. Strongest heparin binding has been observed
in the distal globular end of the long arm. Laminin forms a dense network with
proteoglycans and other molecules and its function is in anchoring the cells in
place. Laminin also has diverse effects on cultured cells because it can alter their
growth, survival, morphology, differentiation, and, motility (Martin, et. aI., 1987).
In connective tissues, fibronectin is the primary adhesive molecule.
Fibronectin is composed of two similar but npt identical polypeptide chains
attached at their carboxy termini by two disulfide bonds to form a dimer of 550
kDa (Hermans, et. aI., 1990). The interaction of glycosaminoglycans with
fibronectin occurs on at least two different sites along the polypeptide chain.
Skorstengaard et. ai. (1986) and Garcia-Pardo et. ai. (1987) sequenced a heparin
binding proteolytic fragment from the carboxy terminus suggesting that these
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residues are important for heparin binding. Each of the fibronectin polypeptides
is composed of 5 or 6 domains that have specific affinity to cells, collagen, fibrin,
and heparin. It is suggested that, in tissues, fibronectin forms tracks along which
cells migrate. Fibronectin also binds to some complement components and
participates in the clearance oftissue debris.
Thrombospondin is synthesized and secreted by cells in vitro, where it is
then able to bind to various cell receptors and become incorporated into the
extracellular matrix. It is a disulfide-linked trimer (450,000 daltons) present in
connective tissues and platelet a granules. This trimeric form ofthe protein
accounts for its ability to promote cell-substratum interactions. These
interactions occur by binding to cell surface heparan sulfate proteoglycans and are
mediated through a heparin-binding domain at the amino terminus of
thrombospondin (Hantai, et. aI., 1991). Thrombospondin stimulates the
proliferation of fibroblasts and smooth muscle cells and in contrast, it inhibits the
proliferation of endothelial cells. Thrombospondin may also serve as both an
attachment protein and an anti-adhesive molecule as shown by its ability to cause
disassembly of focal adhesions in endothelial cells. In addition, thrombospondin
interacts with fibronectin and plasminogen during clot formation.
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THE EXTRACELLUAR MATRIX'S ROLE IN VASCULAR
DISEASE
At initial stages of the disease process, local cell-derived factors such as
low density lipoproteins (LDL) may act on the endothelial cells, resulting in
degradation of the cell surface and adhesion molecules. As a result, the
endothelial cells may react with increased proliferation and production of
extracellular hydrolytic enzymes leading to local degradation ofthe
subendothelial basement membrane. Therefore, massive infiltration of
leukocytes and other cells takes place. Proteases and other mediators released
from the macrophages results in the destruction ofmatrix molecules of the
endothelium. Thus begins the cascade of events that lead to vascular disease such
as atherosclerosis. In addition, a number of investigators have isolated
proteoglycans from the arterial wall and have shown that they precipitate LDL in
vitro. Along with trapping LDL in the extracellular space ofthe arterial wall,
extracellular matrix components contribute to the development of the
atherosclerotic foam cell lesion by enhancing LDL uptake by macrophages. The
interaction of fibronectin with heparin also enhances the uptake of LDL by
macrophages. Therefore, the ability ofcells to attach to an underlying matrix is
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crucial to growth and repair of injury. Finally, studying the interactions of
endothelial cells, matrix components, and heparin is essential to understanding
endothelial repair processes.
HEPARIN'S THERAPEUTIC PROPERTIES
Heparin, a highly negatively charged glycosaminoglycan, is a major
component of mast cell granules. In human umbilical vein endothelial cells,
heparin is able to stimulate the biosynthesis of heparan sulfate in a time and dose
dependent manner (Nader, et. aI., 1989). This stimulation of heparan sulfate
production could provide more substrate for the action of platelet-derived
heparitinase, and therefore, a higher concentration ofantiproliferative molecules
since the release ofheparan sulfate is primarily to the interstitial space where it
may modulate smooth muscle cell proliferation (Hyslop, et. aI., 1993). It is also
possible that the platelet-derived heparitinase may act here to release more
heparan sulfate with antiproliferative activity. In addition to stimulating heparan
sulfate formation, heparin alters the sulfation pattern of this molecule (Hyslop, et.
aI., 1993). This proteoglycan specific response to heparin may explain some of
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its beneficial effects in atherosclerosis. Therefore, there is clinical and
experimental evidence that treatment with low doses of heparin at regular
intervals is able to reduce atherosclerotic effects ( Andriouli, et. aI., 1990). Also,
part of the therapeutic effect of exogenous heparin is its ability to stimulate
endothelial cell growth and migration (Terranova, et. aI., 1985).
It has been suggested that one of the possible causes ofatherosclerosis is a
loss of the vessel content of heparan sulfate because it has been observed that in
atherosclerotic portions ofthe human aorta, the content of heparan sulfate
decreases while that of chondroitin sulfate/dermatan sulfate increases (Hollman,
et. aI., 1989). This is also correlated with age and cholesterol content.
Finally, heparin may also have a protective effect on vascular cells by
scavenging oxygen-derived free radicals which originated from cellular
metabolism. The presence of these reactive molecules can stimulate the
oxidation of low-density lipoproteins by macrophages which are found at the site
of injured endothelium (Hiebert, et. aI., 1991).
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CELL ADHESION AND VASCULAR DISEASE
The migration of monocytes and leukocytes into tissues is the central
event in the inflammatory response leading to vessel injury. In vascular diseases
such as atherosclerosis, it is one ofthe initiating events.
For endothelial cell injury to occur, monocytes must attach to the
endothelium. Little is known of the actual sequence of events leading to
monocyte adhesion in vivo, however, attachment between these cells is mediated
by cell-adhesion molecules (CAM's) present on the surface ofboth cells.
Intercellular adhesion molecule-l (ICAM-l), a major cell-adhesion molecule
found on the surface of endothelial cells binds to the /32 integrin LFA-l which is
present on both mononuclear and polynuclear leukocytes (Poston, et. ai., 1992).
The expression of ICAM-l is upregulated by cytokines released from monocytes
and T-Iymphocytes such as intedeukins, (IL) 1 and 4, and tumor necrosis factor
alpha, TNF-a (Poston, et. ai., 1992).
Human atherosclerotic lesions of all subtypes except fibrous plaques have
recently been demonstrated to show an enhanced expression of ICAM-l (Davies,
et. ai., 1993). The high frequency of ICAM-l expression both on the endothelium
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and on macrophages is unclear, but it may facilitate both antigen recognition by
T-cells and antigen presentation by macrophages (Davies, et. aI, 1993).
P-selectin, another adhesion molecule belonging to the selectin family,
binds carbohydrate ligands on neutrophils, monocytes, and memory T-cells
(Subramaniam, et. aI., 1993). P-selectin is involved in the initial rolling of
neutrophils along endothelial cell monolayers which will eventually result in their
attachment and allow emigration (Smith, 1993). Upregulation of P-selectin
occurs with histamine and is seen within 5 minutes of stimulation, but transient,
where it localizes back to the Weibel-Palade bodies of endothelial cells (Smith,
1993). Jones, et. aI., (1992) recently demonstrated that histamine stimulation of
endothelial cell monolayers promoted neutrophil rolling that was entirely blocked
by anti-P-selectin monoclonal antibodies. P-selectin's role is in the earliest stages
of neutrophil localization while ICAM-l is thought to be involved in the
attachment process. Therefore, one clue to treatment possibilities in vascular
disease could be in blocking either ICAM-l or P-selectin to reduce the number of
neutrophils that localize at sites of inflammation.
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Chapter 3
CULTURE AND IDENTIFICATION OF PORCINE AORTIC
ENDOTHELIAL CELLS
INTRODUCTION
This section reviews the isolation, culture, and identification ofporcine
aortic endothelial cells.
Culture Media
Dulbecco's Modified Eagle's Medium (DMEM) with 4500mg/L Glucose
and L-Glutamine without Sodium Bicarbonate (Sigma, St. Louis, MO) was
supplemented with sodium bicarbonate. The media was completed with 10%
fetal bovine serum (FBS) from Atlanta Biological (Norcross, GA) or Gibco
(Gaithersburg, MD) which was heat inactivated at 65° C for 1hour. In addition,
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2% glutamine and I% penicillin/streptomycin solution (Sigma, St. Louis, MO)
were added to the culture medium. When the endothelial cells needed to be
passaged, a lOx stock oftrypsinlEDTA (Sigma, St. Louis, MO) was diluted in IX
phosphate-buffered saline (PBS).
Endothelial Cell Isolation and Identification
Porcine aortas are sectioned under sterile conditions. Since endothelial
cells are the intimal layer and would slough off first, a brief collagenase digestion
was then performed at 37° C. To optimize endothelial cell recovery, cells were
plated onto 24 well gelatinized plates. Gelatin is required for endothelial cell
growth, but smooth muscle cells may also grow on these plates. Cells were
allowed to grow to confluency in DMEM media supplemented with 10% heat
inactivated FBS, glutamine and penicillin/streptomycin. Only wells that contain
cells with a cobblestone appearance and a confluent monolayer which is
characteristic of endothelial cells were continued. The cells from each of these
wells were maintained as a separate cell line. These wells were eventually
passaged to 150mm plates by trypsinlEDTA treatment and were routinely
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subcultured. If after a period of time, the cells piled up on each other, these wells
were discarded since there was evidence of smooth muscle cell contamination.
The endothelial cells may by stained with antifactor VIII to also determine their
characteristics such as a cobblestone appearance and a confluent monolayer.
Endothelial cells may be passaged approximately 20 times before they are
discarded.
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CHAPTER 4
EXPERIMENTATION TECHNIQUES APPLIED TO
DETERMINE THE EXTRACELLULAR MATRIX PROTEIN
LEVELS
INTRODUCTION
This section reviews the experimental techniques and assays utilized to
determine heparin's effect on the extracellular matrix glycoproteins laminin,
fibronectin and thrombospondin. Two additional techniques will be discussed
which were applied in an attempt to study the cell-adhesion molecules: P-selectin
and Intercellular Adhesion Molecule (ICAM-l). The following techniques were
used for the study of the extracellular matrix glycoproteins: Immunoblots,
immunoprecipitations, dot blots and radioimmunoprecipitations. For the study of
the cell-adhesion molecules, immunofluorescence and the ELISA assay were also
done. These experimental techniques were applied to determine changes in
18
newly synthesized and expressed protein levels at the cell surface and protein
released into the media.
Immunoblots
Endothelial cells were grown to confluency in 150 mm tissue culture
plates at 37° C. Next, a concentration range of heparin was added for a 24 hour
period at the same temperature. The concentration range ofheparin applied was
50 f-lg/ml, 100 f-lg/ml and 200 f-lg/ml, however, one plate did not contain heparin
and served as a control. When fibronectin was going to be examined, the media
was replaced with heat inactivated serum supplement (HISS, JRH Biosciences,
Lenexa, KS) at the time the heparin was added to prevent the primary antibody
from reacting with the FBS in the media. When cycloheximide was applied,
heparin was applied for as long as the cycloheximide was added i.e. 4 hours.
Cycloheximide (Sigma, St. Louis, MO) was added at a 1:1000 dilution from a
concentration of 1 mg/ml in selected experiments..
After the incubation time, the media was removed and set aside for further
analysis. The cells were harvested by adding IX PBS and scraping the surface of
the plates with a rubber policeman. The cellular material was then collected by
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centrifugation and resuspended in 2X sample buffer. In addition, 0.1%
bromophenol blue was added as a tracking dye. The samples were vortexed,
boiled for 5 minutes, pulsed in a microfuge and loaded onto the gel. The cell-
surface proteins were analyzed and identified by SDS-PAGE using the Sturdier
apparatus (Hoefer Scientific Instruments, San Francisco, CA). The proteins were
transferred electrophoretically onto nitrocellulose for 4 hours at 60 volts using the
Transphor device (Bio-Rad Laboratories, Richmond, CA). For larger molecular
weight proteins, a longer transfer was required. (See Figure 4.1 page 32).
After transfer, the nitrocellulose was blocked overnight in blotto
containing 5% non-fat milk, 3% bovine serum albumin, sodium azide, and 10%
lOX Tris-Buffered Saline, (TBS). After blocking, one lane was cut from the
nitrocellulose and kept in block to be used as a secondary control. After
,blocking, the other piece of nitrocellulose was rinsed three times for 10 minutes
with IX Tris-buffered saline and O.l%'tween-20 (TBST) at room temperature.
Next, to the blotto was added the commercially available polyc1onal primary IgG
antibody developed in rabbit to either laminin or fibronectin (Sigma, St.Louis,
MO) at a 1:1000 dilution for 2 hours at 37°C. The primary Ab was then rinsed
off five times for five minutes with TBST at room temperature. At this time the
secondary control lane was also rinsed with TBST. Both pieces were then placed
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in blotto containing donkey anti-rabbit biotinylated secondary antibody (Sigma,
St. Louis, MO) at a dilution of 1:10,000 overnight on a rocker at 4°C.
The following day, the nitrocellulose pieces were again washed three
times for 10 minutes with TBST at room temperature and incubated for a
minimum of two hours with Extra-Avidin Phosphatase (Sigma, St. Louis, MO) at
a dilution of 1: I0,000 in TBST also at room temperature. Again, blots were
washed in TBST, three times for 10 minutes at room temperature. Blots were
then placed in alkaline phosphatase buffer for 5 minutes at room temperature and
then this buffer was discarded. For the development, 50 III ofBCIP (Sigma, St.
Louis, MO) and 100 III of NET (Sigma, St. Louis, MO) was added to 50 mls of
alkaline phosphatase buffer and allowed to develop in the dark for a 1 to 4 hour
time frame. (See Figure 4.2 page 33).
Blots were then scanned on an LKB Bromma Ultroscan XL Enhanced
Laser Densitometer (Bromma, Sweden) to quantitate the amount of protein
present.. Each lane was scanned and the baseline absorbance unit value (AU) for
a set of lanes was averaged together. This value was either added or subtracted
from each AU result for the individual lanes depending on the intensity of the
lane. In addition, the secondary control AU value was subtracted from each
result.
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Immunoprecipitations and Dot Blots
The media from the 150 mm plates was dialyzed for a minimum of
48 hours at 4°C with at least four milli-Q water changes to dialyze out the
salts in the media. One milliliter ofmedia from each sample was used to
immunoprecipitate the proteins of interest while the rest was evenly run
through a dot blot apparatus (Bio-Rad Laboratories, Richmond, CA). The
dots were then developed as described above for immunoblots and
scanned on the densitometer.
For the immunoprecipitation, 15% protein A Sepharose beads
(Sigma, St. Louis, MO) and a nonimmune IgG rabbit antibody (Sigma, St.
Louis, MO) was added at a dilution of 1: 1000 to 1ml of media. This was
placed on a rocker at 4°C overnight. The following day, the samples
were centrifuged and the beads were discarded. To the supernatant, 15%
protein A Sepharose beads were added along with the commercially
available polyclonal IgG antibody developed in rabbit to either laminin or
fibronectin at a 1:1000 dilution. These samples were again incubated
overnight at 4° C on a rocker. However, one sample remained in the
nonimmune IgG Ab for the rest of the protocol and served as a control.
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The next day, the samples were centrifuged again and the supernatant was
discarded. The beads were then washed with 30 times their volume with
IX TBS. After each washing, the samples were centrifuged and the
supernatant was discarded. After the final rinse, 2X sample buffer was
added to each sample plus 0.1 % Bromophenol blue was also added as a
tracking dye. These samples were then analyzed by SDS-PAGE,
transferred to nitrocellulose and then developed as described previously
for immunoblots. In addition, these blots were also scanned on the
densitometer to quantitate the amount of protein present.
Radioimmunoprecipitation
To perform the radioimmunoprecipitation, endothelial cells were
grown to confluency in 6 well tissue culture plates. To these cells, 50
I' Ci/well of 35S_met, (Dupont, Boston, MA) low-methionine media,
(Dulbecco's Modified Eagle's Medium DMEM), and a concentration
range of heparin as previously described in the immunoblot section was
added for a 24 hour period. If fibronectin was the protein of interest,
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HISS was again added to the medium instead of fetal bovine serum since
the antibody to fibronectin would also recognize and bind to the
fibronectin found in the media. The next day, the media was separated
from the cells and the cells were harvested with IX PBS containing 1%
CHAPS. Then the protocol was followed according to the
immunoprecipitation procedure for both the media, and cellular material.
For the thrombospondin protein, a ~onimmune mouse IgG (Sigma, St.
Louis, MO) was added at a 1:1000 dilution, followed by a 1:1000 dilution
ofmonoclonal IgG antibody to thrombospondin from mouse ascites fluid
(Sigma, St. Louis, MO). In addition, for this assay one sample remained
in the nonimmune Ab and served as a control for the rest of the procedure.
Also, 0.5 M PMSF, 0.5 M benzamide, and 5 mM caproic acid (all Sigma,
St. Louis, MO) protease inhibitors were added to prevent protein
degradation. After the proteins were separated by SDS-PAGE, the gel was
soaked in Destain I which contains 50% methanol, 10% acetic acid and
2% glycerol for 30 minutes, dried with the gel slab dryer (Biorad,
Richmond, CA), and then exposed to X-ray film (Kodak, Rochester, NY)
at - 70° C for one month. The film was developed in a dark room using
commercially available developer (Kodak, Rochester, NY) for 3 minutes,
followed by 2 minutes in a stop bath consisting of 3.5% acetic acid and
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then finished with fixer (Kodak, Rochester, NY) for 3 minutes. The
protein bands that developed were also scanned on a densitometer to
quantitate the amount of protein present. (See Figure 4.3 page 34).
Immunofluorescence
In addition, to the protocols previously described, the
immunofluorescence and the ELISA assay were also employed to attempt
to study P-selectin and ICAM-I.
Endothelial cells were grown on 0.5% gelatinized coverslips.
Since P-selectin is a protein which is only expressed during endothelial
cell damage or injury, activation is required. Once the cells were
confluent, activation was performed with 5 units of IL-l p, initial
concentration of 5 x 106 for a 5 hour time frame. Some coverslips were
activated and also exposed to 200 /-lg/ml of heparin. When activation was
unsuccessful, histamine was used as an activator at a O.OOOIM solution,
according to Subramaniam, et. at, (1993) for 5 minutes.
Following activation, P-selectin is only expressed on the cell-
surface for a short time before its transferred to the Weibel Palade bodies
of endothelial cells. Cells were washed 3 times for 5 minutes with cold
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IX PBS. Next, the cells were solubilized with methanol for a maximum
of 5 minutes and fixed with commercially available fixative (Amresco,
OH). This was followed by 3 washes for 5 minutes with cold IX PBS.
The cells were then incubated for 1hour at 37° C with primary
monoclonal P-selectin IgG antibody (Becton Dickinson, San Jose, CA).
Again the cells were washed 3 times for 5 minutes with IX PBS. After
the washes, the coverslips were incubated in the dark at room temperature
for 1 to 2 hours with a 1: 160 dilution with Dichlorotriazinyl Amino
Fluorescein (DTAF) conjugated affinity purified goat anti-mouse IgG,
H+L secondary antibody (Jackson Biological Laboratories, West Grove,
PA). Next, 3 washes for 5 minutes with IX PBS were performed in the
dark at room temperature. Finally, coverslips were mounted on slides
with 30 f.11 oftris buffered Mowio14-88 (Calbiochem-Novabiochem
Corporation, La Jolla, CA), ph 8.5/slide. Slides were stored in the dark
and were viewed within 24 hours with a Nikon microscope equipped with
epifluorescence.. For controls, some coverslips were exposed to 2° Ab
only, while some were exposed to no antibodies at all.
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ELISA
Endothelial cells were grown in 96 well tissue culture
plates. Again, cells were activated with either 5 units of IL-I f3 or 5
minutes with histamine at a concentration of IX10-4 (Sigma, St. Louis,
MO). Media was removed dialyzed and run through a dot blot (Biorad,
Richmond, CA) and developed as previously described in the immunoblot
section. In addition, in some experiments media was also analyzed by the
ELISA assay. The media was allowed to sit in a microtiter plate for
several days, removed, and commercially available fixative (Arnresco,
Solon OR) was applied to retain the proteins that were released from the
media. The protocol was then followed as described here. Following
activation, cells were fixed with commercially available fixative. Cells
were then exposed to primary monoclonal IgG P-selectin antibody
developed in mouse (Becton Dickinson, San Jose, CA) at a I: 1000
dilution in blocking buffer containing 5% non-fat dry milk, 6 mM sodium
azide, 3% bovine serum albumin and lOX tris buffered saline for I hour at
37° C. This was followed by 5 washes for 5 minutes with IX TBS at
room temperature. Next, goat anti-mouse biotin conjugated secondary
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antibody (Sigma, St. Louis, MO) was then added to the cells at a 1:10,000
dilution in blocking buffer overnight at 4° C. The following day, the
secondary antibody was removed and the cells were washed with IX TBS,
3 times for 10 minutes at room temperature. Cells were then placed in
Extra-Avidin Phosphatase (Sigma, St. Louis, MO) at a 1: 10,000 dilution
for 1 hour in IX TBS at 37°C. The Extra-Avidin Phosphatase was
removed and the cells were again rinsed with IX TBS, 3 times for 10
minutes at room temperature. For the development, 50 !J.I ofpara-
nitrophenyl phosphate (Zymed, San Francisco, CA) was added to 250 !J.I
of lOX 1 M 2-amino-2methyl-l,3-propandiol pH 10.0 (Zymed, San
Francisco, CA) per 2.5 ml ofmilli-Q water. Controls consisted ofblank
wells which contained IX TBS only, positive controls which consisted of
the enzyme and substrate and finally wells with secondary antibody only.
Plates were read on the spectrophotometer (MR700 Dynatech
Laboratories, Chantilly, VA) set at 410 nm. When this development was
unsuccessful, development was tried with using the enzyme Extra-Avidin
Peroxidase (Sigma, St. Louis, MO) and then adding the substrate which
was 1 tablet of2,2 Azino-Bis (3-ethylbenzthiazoline-6-sulfonic acid)
(Sigma, St. Louis, MO) in 100 ml of 0.05 M phosphate-citrate buffer
pH5.0 and then 25 !J.I of 50% H202was added.
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Intercellular Adhesion Molecule (ICAM-l) is also a protein which is only
expressed during endothelial cell damage or injury. However, following
activation, the protein should be located on the cell-surface from 6 hours to 24
hours according to Hahne et. aI., (1993). Activation was attempted with Tumor
Necrosis Factora (Sigma, ST. Louis. MO) at a lOng/ml concentration (Ritchie,
et. aI., 1991), NiCl2 2mM solution according to Goebeler, et. aI., (1993) and PMA
100 ng/ml (Ritchie, et.al.,1991). Following activation, the protocols previously
described were followed in an attempt to study ICAM-l protein levels.
Northern Analysis
Total cellular RNA was isolated according to the Gentra Systems., Inc.
(Minneapolis, MN) protocol with reagents provided. The amount ofRNA
isolated was determined with Absorbance readings at 260 nm and purity ofthe
RNA was determined from the ratio of A2601A28o, 9 Jl g of total cellular RNA was
loaded onto a 1% Agarose gel with 15% formaldehyde added and 10% lOX
MOPS buffer which contains MOPS, 3 M sodium acetate, and 0.5 M EDTA. Gel
was electrophoresed overnight at 25 volts. Next day, the gel was soaked in 0.1 M
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Tris-Cl, for 30 minutes and then placed in a solution of 50 mM NaOH plus 10
mM NaCl for also 30 minutes. Finally, before transfer the gel was placed in 20X
sse which contains 3 M NaCl plus 0.3 M citric acid for 30 minutes. Transfer to
a nylon membrane was carried out by electroblotting (Bio Rad, Richmond, CA) at
ImA overnight in 0.5X TBE which contains 44.5 mM Tris-base, 44.5 roM Boric
acid, and 1.25 roM EDTA at 4°C. The nylon membrane was crosslinked under a
UV light and then placed in 30ml of pre-hybridization solution (KH2P04, 2M, 5X
SSC, 5X Denhardt's solution, salmon sperm DNA, and 50% formamide) at
37 °C. The following day, the biotinylated cDNA (Oligos etc., Wilsonville, OR)
was restored with 100 f.ll ofDEPC H20 at a concentration of 1 mg/ml, boiled for
5 minutes and then added to the pre-hybridization solution along with t-RNA
baker's yeast (Sigma, St. Louis, MO) at a 1:200 dilution. Since the Tm of the
probe was 50 °C and the hybridization occurs at 5-15 °C below the Tm according
to Farrell, R.E., (1993), all steps from the pre-hybridization to the development
occurred at 37°C. Following hybridization for 96 hours at 37°C, the nylon
membrane was washed 2 times for 15 minutes with lXSSC plus 0.1 %SDS
followed by 2 rinses with 0.25XSSC plus 0.1 % SDS. The nylon membrane was
then placed in lectin block which is made up of 1% fish gelatin, 1% PVP, 0.1%
sodium azide, 0.1 % Tween-20, and 10X TBS for 24 hours. The next day, the
lectin block was removed and the nylon membrane was washed three times for 10
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minutes with TBST. This was followed by Extra-Avidin Phosphatase (Sigma,
ST. Louis, MO) added at a 1:10,000 dilution in TBST at 37°C overnight. Extra-
Avidin Phosphatase was removed and the nylon membrane was again washed
three times for 10 minutes with TBST. The nylon membrane was then placed in
alkaline phosphatase buffer for 5 minutes and then the buffer was discarded. For
the development, 50 f.J I ofBCIP and 100 f.J I ofNBT was added to 50 mls of
alkaline phosphatase buffer and allowed to develop in the dark for a 1 to 4 hour
time frame.
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CHAPTER 5: RESULTS AND DISCUSSION
To study the effect of heparin on the cell-adhesion molecule P-selectin,
porcine aortic endothelial cells were stimulated with Il-l fJ for a 5 hour
stimulation time. The cells were harvested, and the results of the immunoblot are
provided in Figure 5.1. P-selectin is a membrane protein ,Mr 140 kDa, according
to Kunzendorf et. ai. (1993). Since there was not any significant change from the
control lanes, to the stimulated lanes of II-I fJ, and 11-1 fJ plus 200 f.1 glml of
heparin treatment applied, it was determined from literature reviews that P-
selectin is being expressed on the cell-surface for a brief time, approximately 5
minutes and then transferred back into the Weibel-Palade bodies of endothelial
cells. In addition, according to Subramaniam, et. aI., (1993) histamine appeared
to be a better stimulator of endothelial cells to get the P-selectin protein released
from the Weibel-Palade bodies and expressed on the cell surface. Histamine was
also applied since 11-1 fJ is developed in humans and activation may not have
occurred since the assay was run on porcine aortic endothelial cells. Therefore,
using a chemical such as histamine, activation should occur since there is no
35
species interaction occurring. Another immunoblot was performed (Figure 5.2).
Again, there was not a change between the unstimulated cell lanes, to the
stimulated cell lanes, and to lanes stimulated with histamine and 200 Ji g/ml of
heparin treatment. Activation was also attempted with TNF-a for P-selectin
according to Hahne et. al (1993). Maximum surface expression for P-selectin
should be between 4 and 8 hours after stimulation. Therefore, endothelial cells
were stimulated with TNF-a for 4 hours, harvested and the results of the
immunoblot are provided (Figure 5.3). Again, there appeared to be no change in
protein levels from the control lane, to the activated lane, and to the activated
lane with the addition of200 Ji g/ml ofheparin treatment. No further
immunoblots were performed.
An immunofluorescence protocol was then performed using histamine as
an activator to see if the location of the molecule could be followed.
Unfortunately, no fluorescence was observed only autofluorescence of the
endothelial cells themselves in the control slides was observed. No data is
provided for this protocol.
Next, an ELISA assay was run since activation of endothelial cells would
result in the expression of this protein on the cell surface. This assay detects
expressed protein only as opposed to the immunoblot and immunofluorescence
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which detect both newly synthesized and expressed protein. In addition, a time
course from 2 minutes to 1hour with histamine was done to possibly determine
an optimum time for stimulation. From Experiment 1, 7 minutes appeared to be
the optimum time and was the stimulation time applied for Experiments 2
through 4. Data is provided in TABLE 5.1.
Table 5.1. ELISA results for P-selectin Adhesion Molecule
OD410
Treatment Exp.1 Exp.2 Exp.3 Exp.4 Exp. 4 read
24hrs later
cells without 0.3± 0.031 ± 0.020± 0.025± 0.15±
stimulation 0.1 0.003 0.005 0.003 0.08
cells with 7 minute 0.9± 0.033± 0.026± 0.025± 0.09±
histamine 0.2 0.005 0.003 0.002 0.04
stimulation
cells with 7 minute
histamine N/A 0.029± 0.300± 0.042± 0.23±
stimulation +200 0.001 0.005 0.005 0.07
j..l g/ml heparin
2° Ab control 0.7± 0.031 ± 0.017± 0.036± 0.19±
0.2 0.003 0.001 0.002 0.08
positive control N/A N/A N/A 0.023 0.052
2 minute histamine 0.7± N/A N/A N/A N/A
stimulation 0.1
5 minute histamine 0.9± N/A N/A N/A N/A
stimulation 0.1
10 minute histamine 0.8± N/A N/A N/A N/A
stimulation 0.1
20 minute histamine 0.8± N/A N/A N/A N/A
stimulation 0.2
30 minute histamine 0.7± N/A N/A N/A N/A
stimulation 0.2
1 hour histamine 0.7± N/A N/A N/A N/A
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*Values are means ± SED of quadruplicate wells except for the positive control. Data
from four independent experiments are shown except for experiment 4 which was reread
24 hours later.
As one can see there was not enough difference between the values to
notice any significant changes. Therefore, no further experimentation was
pursued for this molecule.
Activation is also required for the cell-adhesion molecule, ICAM-l.
According to Hahne, et. aI., (1993), cell surface expression ofICAM-l is still
elevated 24 hours after activation with TNF-a in human umbilical vein
endothelial cells. Porcine aortic endothelial cells were activated with TNF-a for
4 hours, one plate was exposed to TNF-a and 200 f.1 glml of heparin treatment,
and one plate served as a control (Figure 5.3). Unfortunately, there did not appear
to be any change in protein levels from the control lane, to the activated lane with
TNF-a, and the activated lane with TNF-a and 200 f.1 glml of heparin treatment.
ICAM-l is a protein with Mr from 76-114 kDa according to Becton Dickinson
Advanced Cellular Biology, (1993). There did not appear to be any protein band
in this range of molecular weight. For the media from these cells, an ELISA was
performed. The results will follow the immunoblots in TABLE 5.2.
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Another immunoblot was run using TNF-a as the activator for 6 hours and
24 hours to see if there is an optimum time for activation of the ICAM-l protein
on the cell surface. The endothelial cells were harvested and the immunoblot is
provided (Figure 5.4). Only one molecular weight protein band developed in the
6 hour lanes, that did not appear on the secondary antibody positive control lane,
or the ahour lanes, however, the molecular weight is approximately 120 kDa and
is out of the range for the molecular weight of the ICAM-l protein superfamily.
The media from these cells was also analyzed by the ELISA method and will
follow in TABLE 5.2.
Since activation was minimal, activation was attempted with a 2mM
NiCh solution according to Goebeler, et. aI., 1993. Unlike TNF-a which is a
human recombinant, chemical activation with NiClz would eliminate the species
difference that is occurring. Stimulation was done for 6 hours with NiCl2 and
TNF-a. Endothelial cells were harvested and the immunoblot is provided (Figure
5.5). Again, there did not appear to be any difference between the ahour lane,
the NiClz treated lane, the TNF-a treated lane, the NiCl2 treated lane plus 200
f.1 glml of heparin treatment lane, and the TNF-a treated lane plus also 200
f.1 glml of heparin treatment applied. The media from these cells was also run on
an ELISA and the results are also provided in TABLE 5.2.
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Finally, a phorbol ester called PMA, phorbol-12-myristate 13-acetate, was
applied according to Ritchie et. al., (1991). In addition, some of the lanes were
run nonreduced. According to the Hedman et. aI., (1992) article, ICAM-l Mr is
approximately 200 kDa under nonreduced conditions. The results of the
immunoblot are provided (Figure 5.6). Again, no difference was observed
between the 0 hour lane, the stimulated lanes, and the secondary antibody control
lanes. All activators, NiCI2, PMA, and heparin were applied for 24 hours. The
results of the ELISA are provided below in TABLE 5.2
TABLE 5.2: ELISA Results ofICAM-l released into the media
OD410
Exp.l Exp.2 Exp.3 Exp.4 Exp.
Treatment 5
cells without .06± .074± .073± .058± .04±
stimulation .01 .008 .004 .002 .02
4 hour stimulation N/A N/A .076± .060± N/A
with TNF-alpha .005 .003
4 hour stimulation N/A N/A .081± .068± N/A
with TNF-alpha plus .005 .002
200 f.1 g/ml heparin
6 hour stimulation .08± .076± N/A N/A .022±
with TNF-alpha .01 .004 .002
6 hour stimulation N/A N/A N/A N/A .023±
with TNF-alpha plus .001
200 f.1 g/ml heparin
6 hour stimulation N/A N/A N/A N/A .04±
with NiCl2 .02
6 hour stimulation N/A N/A N/A N/A .026±
with NiCl2 plus 200 .005
f.1 g/ml heparin
24 hour stimulation .061 ± .076± N/A N/A N/A
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with TNF-alpha .009 .004
positive control .9± .5± .23± .13± 1.3±
.1 .2 .02 .03 .2
secondary antibody .069± .04± .06± .035± .015±
control .005 .02 .02 .008 .001
Values are Means ±SED for quadruplicate wells except for the positive control. Results
from 5 different experiments are provided. Absorbance readings were read at 41 Onm.
No further work was perfonned on this protein. Next, the extracellular
matrix proteins fibronectin, thrombospondin, and laminin were studied.
Fibronectin is an extracellular matrix glycoprotein with Mr of 220 kDa
under reduced conditions. A radioimmunoprecipitation was performed for
fibronectin with endothelial cells exposed to 100 J1 glml of heparin treatment for
a 24 hour incubation time. The results are provided (Figure 5.7). Fibronectin
protein levels are elevated with heparin treatment as compared to the control lane.
The media was also analyzed by radioimmunoprecipitation (Figure 5.8). With
100 J1 glml of heparin treatment, released newly synthesized protein levels are
also elevated. by comparing the control lanes to the heparin treated lanes.
Next, to observe if there was a concentration dependent effect when
heparin treatment was applied, a concentration range of heparin treatment was
applied to endothelial cells for a 24 hour period. A radioimmunoprecipitation
assay was used to determine if heparin treatment was affecting the newly
synthesized protein levels at the cell-surface (Figure 5.9). When 50, 100, and 200
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J.lg/ml of heparin were applied, an increase in protein levels at the cell-surface is
observed by comparing the heparin treated lanes to the control lane. In addition,
the media was also analyzed by radioimmunoprecipitation (Figure 5.10). The
newly synthesized released protein levels are also elevated by comparing the
treated lanes, to the control lane. Next, fibronectin was analyzed by an
immunoblot to determine if both the newly synthesized and expressed protein
levels are increasing (Figure 5.11). Again by comparing the control lane, to the
heparin treated lanes, one can see that protein levels are increasing. The media
from these cells was analyzed by immunoprecipitation (Figl;}re 5.12). Protein
levels are again increased by comparing the heparin treated lanes, to the control
lane. Two bar graphs are provided from the densitometric AU values obtained
from these experiments (Figures 5.13 and 5.14). Error bars are the standard error
of deviation. One bar graph is for the protein on the cell-surface and the other is
for the protein released into the media.
Next, the extracellular matrix glycoprotein thrombospondin was analyzed.
Thrombospondin is a protein that migrates as a single band ofMr 450 kDa during
SDS-PAGE under nonreduced conditions. A radioimmunoprecipitation was
performed with endothelial cells exposed to 100 J.lg/ml ofheparin treatment for a
24 hour incubation time. Refer back to Figure 5.7. When heparin treatment was
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applied, newly synthesized cell-surface protein levels are reduced a~ compared to
the control lanes, In addition, when the media was analyzed from this
experiment, it was observed that heparin treatment reduced released protein
levels as compared to the control lanes by referring back to Figure 5.8 and
comparing treated lanes, to the untreated lanes. To determine if there was a
concentration dependent effect ofheparin treatment on thrombospondin protein
levels, a concentration range of heparin was applied.
Therefore, endothelial cells were exposed to a heparin concentration range
from 50 !J.g/ml to 200 !J.g/ml for a 24 hour period. Two radioimmuno-
precipitations were performed for the cell-surface proteins and proteins released
into the media (Figures 5.15 and 5.16). For both experiments, newly synthesized
protein levels are decreasing at the cell-surface and also the protein released into
the media when heparin treatment is applied. Two bar graphs are provided with
the standard error of deviation as the error bars (See Figures 5.17 and 5.18).
Third, the extracellular matrix glycoprotein laminin was studied. The
laminin molecule is composed of three polypeptide chains, A, B1, and B2 with a
Mr of350-400 kDa, 215 kDa, and 205 kDa, respectively. Depending on the
degree of glycosy1ation, the A chain has variability in its molecular weight and
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also the B1 chain and B2 chain may migrate as a single band also depending on
glycosylation and the assay applied.
When heparin treatment is applied, laminin protein levels are affected. A
concentration range ofheparin treatment from 50 Ilg/ml to 200 Ilg/ml of heparin
treatment was applied to the endothelial cells for a 24 hour period. Laminin was
analyzed by immunoblots for the cell-surface proteins and immunoprecipitations
for the released protein in the media. When heparin treatment was applied, newly
synthesized protein and expressed protein levels are increased at the cellular level
for both the A and B chains (Figure 5.19). For the protein released into the
media, levels remained about the same regardless if heparin was applied (Figure
5.20). The 400 kDa A chain subunit did not appear in the media. Another
immunoblot was run for the cell-surface proteins and another
immunoprecipitation was run forthe protein in the media (Figure 5.21 for the
cell-associated protein). Again the treated lanes have an increase in protein levels
for both the A and B chains. The 400 kDa A chain did not transfer as well
though. The media was again analyzed by immunoprecipitation and for the
protein released into the media, levels remained about the same. Refer back to
Figure 5.12 and compare treated lanes, to the untreated lane. Next, a
radioimmunoprecipitation was performed for both the cell-associated protein and
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protein released into the media (Figure 5.22 for the laminin cell-associated
protein). Again newly synthesized laminin protein levels are increasing when
heparin treatment was applied. When the media was analyzed, the newly
synthesized 400 kDa protein subunit is increasing while the 200 kDa protein
subunit is decreasing when heparin treatment is applied (Figure 5.23). Two bar
graphs are provided for the lamiriin cell associated protein and protein released
into the media. Error bars are the standard error of deviation (Figures 5.24 and
5.250. However, sometimes when heparin treatment is applied, laminin protein
levels at the cell surface also decrease.
For example, when two radioimmunoprecipitations were performed on
cell-associated proteins on the same cell line, heparin treatment decreased newly
synthesized laminin protein levels (Figure 5.26). Two radioimmunoprecipitations
were also performed for the proteins released into the media, and results were
consistent with previous experiments i.e. heparin treatment decreased newly
synthesized 200 kDa subunit protein levels, but increased the 400 kDa subunit
protein (Figure 5.26).
When experiments were run on the same endothelial cell line that was
nonconfluent as opposed to a confluent cell line, similar results were obtained.
Two immunoblots were performed on the same endothelial cell line with heparin
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treatment applied, however, in one experiment the cells were subconfluent
(Figure 5.27) and in the other experiment, the cells were confluent (Figure 5.28).
In both cases, newly synthesized and expressed protein levels decreased at the cell
surface. The 400 kDa protein did not appear in Figure 5.27 though. The media
from these two experiments was analyzed by immunoprecipitation, laminin
expressed protein levels and newly synthesized protein levels remained about the
same for the proteins released into the media which was consistent with previous
experiments-. No Figure is provided for the media results since the data is
consistent with previous experiments.
Since there is no published information in the literature on laminin protein
level changes as a result ofheparin treatment and because the results were so
varied not within the same cell line but between cell clones and were not affected
by changes in serum or heparin lots, more experimentation was performed.
Endothelial cells were exposed to heparin treatment and cycloheximide to
determine if blocking new protein synthesis would affect laminin protein levels
(Figure 5.28). When heparin and cycloheximide treatments were applied, laminin
protein levels are reduced as compared to the control lanes, change was observed
at the 400 and 200 kDa protein band, A bar graph is provided for the
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cycloheximide data (Figure 5.29). The released laminin protein in the media was
not affected by cycloheximide and therefore no figure is provided.
Next, RNA was isolated to determine if heparin was affecting RNA levels
since heparin affected laminin protein levels. Total cellular RNA was isolated
and run on a 1% agarose gel (Figure 5.30). The RNA was stained with ethidium
bromide however, when the gel was transferred to a nylon membrane and probed
with a cDNA complementary to the Bl region of the laminin molecule, no
banding pattern was observed for the mRNA..
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Immunoblot of P-selectin. SDS-PAGE was run of cell-surface proteins as described in
Chapter 4, the experimentation section. Electrophoresis was carried out in 10% reducing
polyacrylamide gel and probed for P-selectin with commercially available antibody.
The samples applied were: Lane 1, biotinylated molecular weight marker, Lanes 2 and 5,
ohour controls, no stimulation of endothelial cells, Lanes 3 and 6, 5 hour stimulation of
endothelial cells with 11- I~, and Lanes 4 and 7, endothelial cells were stimulated with
heparin and 11- I~ for 5 hours.
Figure 5.1: An Attempt to Probe for P-selection
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Immunoblot ofP-selectin. SDS-PAGE \vas run of cell-surface proteins as described in
Chapter 4. the experimentation section. Electrophoresis was carried out in 10% reducing
polyacrylamide gel and probed for P-selectin with commercially available antibody.
The samples applied were Lane I. biotinylated molecular weight marker, Lanes 2 and 5.
ohour controls, no stimulation of endothelial cells, Lanes 3 and 6, 5 hour stimulation of
endothelial cells with I1-I~. and Lanes 4 and 7, endothelial cells were stimulated with
heparin and 11-1 ~ for 5 hours
Figure 5.1: An Attempt to Probe for P-selection
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Immunoblot of P-selectin. SDS-PAGE was run ofcell-surface proteins as described in
Chapter 4,the experimentation section. Electrophoresis was carried out in 8% reducing
polyacrylamide gel and probed for P-selectin with commercially available antibody.
The samples applied were: Lane 1, biotinylated molecular weight marker, Limes 2 and S,
ohour controls, no stimulation ofendothelial ceIls, Lanes 3 and 6, stimulation of
endothelial cells with histamine, and Lanes 4 and 7, endothelial cells were stimulated with
heparin and histamine.
Figure 5.2: An Attempt to Probe for P-selection
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Immunoblot of P-selectin. SDS-PAGE was run of cell-surface proteins as described in
Chapter 4,the experimentation section. Electrophoresis was carried out in 8% reducing
polyacrylamide gel and probed for P-selectin with commercially available antibody.
The samples applied were: Lane I, biotinylated molecular weight marker, Lanes 2 and 5,
ohour controls, no stimulation of endothelial cells, Lanes3 and 6, stimulation of
endothelial cells with histamine, and Lanes 4 and 7, endothelial cells were stimulated with
heparin and histamine.
Figure 5.2: An Attempt to Probe for P-selection
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Immunoblot ofP-seleetin and ICAM-I. SDS-PAGE was run ofcell-surface proteins as
described in Chapter 4, the experimentation section. Electrophoresis was carried out in
8% reducing polyacrylamide gel and probed for P-selectin (Lanes 3-5) and ICAM-I
(Lanes 6-8) with commercially available antibody. The samples applied were: Lane 1,
rainbow molecular weight marker, Lane 2, biotinylated molecular weight marker, Lanes 3
and 6,0 hour controls, no stimulation ofendothelial cells, Lanes 4 and 7, endothelial cells
were stimulated with TNF-a for 4 hours and Lanes 5 and 8, endothelial cells were
stimulated with TNF-a and 200 Ilglml of heparin for 4 hours.
Figure 5.3: An Attempt to Probe for P-selection and ICAM-l Cell-
Associated Protein
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Immunoblot ofP-selectin and ICAM-l. SDS-PAGE was run ofcell-surface proteins as
described in Chapter 4, the experimentation section. Electrophoresis was carried out in
8% reducing polyacrylamide gel and probed for P-selectin (Lanes 3-5) and ICA,\1- I
(Lanes 6-8) with commercially available antibody. The samples applied were: Lane I,
rainbow molecular weight marker, Lane 2, biotinylated molecular weight marker, Lanes 3
and 6, 0 hour controls, no stimulation of endothelial cells, Lanes 4 and 7, endothelial cells
were stimulated with TNT-a. for 4 hours and Lanes 5 and 8, endothelial cells were
stimulated with TNF-a. and 200 Ilg/m1 of heparin for 4 hours.
Figure 5.3: An Attempt to Probe for P-selection and ICAM-l Cell-
Associated Protein
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1mmunoblot of ICAM-I. SDS-PAGE was run of cell-surface proteins as described in Chapter
-1, the experimentation section. I::lectrophoresis was carried out in H% reducing
polyacrylamide gel and probed for ICAM-l with commercially available antibody. The
salllplt:s applit:tl wt:rt:: Lant: I, rainbuw mult:l:ular wt:ighl markt:r, Lant: 2, biulinylalt:u
molecular weight marker, Lanes 3 and 6, Ohour controls, no stimulation of endothelial cells
with T:.JF-a., Lanes 4 and, endothelial cells were stimulated with TJ\'F-a. for 6 hours, Lanes 5
and 8, endothelial cells were stimulated with TNF-afor 24 hours, and Lane 9, secondary
antibody control.
Figure 5.4: An Attempt to Probe for (CAM 1
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Il11l1lulloblot of IC\ ~\'1-1 SDS-P.\GE IV as run lIt' cell-surface proteins as described in Chapter
.1. the t:\penmt:lltauon sectIon l:-.Iectroplluresls 'vas calTled uut m :S% reducmg
pui\am lamide gel and prubed for IC ..\M- i with commerciaily availahle antihody The
~a!l!pie~ <lfJplieJ were Lalle I. rainuuw molecular weight marKer. Lalle :::. biolil!)'laleJ
m,',kcular I\eight marker. Lanes:; and 6. Ohour controls. no stimulation of endothelial cells
',\ ilh T~F-(j.. Lanes -l and. endothelial celb were stimulated with T1\F-o. fur b hours. Lanes 'i
,Ind S. c:ldothelial cells were stimulated with T:\F-oJor 2-l hllurs. and Lane 'J. secundaf\
antibuu\' cantrol
Figure S.4: An Attempt to Probe for leA'1 1
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Ll1lllunoblot of IC\lvl-\ SDS-PAGE ~vas run uf cell-surface proteins as descrihed in
l'~l"pter -l. the e'perimentatlOn section. bJectrophoresis was carried out in ljU'o redUCing
pll!vacrvlamide gel and prohed tor Ie ;\1\1-! with commerciaiiy availahle antibody The
,all'pll" <:!~pljeJ Ivele. Lalle I. biL1linyialeJ lIIob:ul<:!1 Iveighllll<:!1 l-.er. Lalle 2.0 hoU!
(ontroL no stimulation ,)1' endothelial cells. Lane 3. endothelial cells were stimulated v"ith
T'W-u !c)r 6 hOUfS. Lane 4. endothelial cells ,vere stimulated with Tl\F-a and 200 pg/ml
()~. heparin tor 6 hours. Lane 5. endothelial cells were stimulated \vith 'liCl: tor 6 hours.
! ..1I1\: 0. endothelial cells were stimulated with !'.iC!:and 200 ~!g/ml of heparin for 6 hours.
and lane 7 sC('I.mdary antibody ('l)ntrol
Figure 5.5: Cell-Surface Stimulated with Tumor 1\ecrosis Factor
Alpha and 1\ickel Chloride.
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Immunoblot ofICAM-l SDS-PAGE \vas run of cell-surface proteins as
described in Chapter 4, the experimentation section. Electrophoresis was carried out in
8% polyacrylamide gel and probed for lCAM-l \vith commercially available antibody
The samples applied were: Lane I, rainbow molecular weight marker, Lane 2,
biotinylated molecular weight marker, Lanes 3, 0 hour controls, no stimulation of
endothelial cells, Lane 4, endothelial cells were stimulated with f\iCh for 24 hours and
\vere run nonreduced, Lanes 5, endothelial cells were stimulated with PMA for 24 hours
and were run nonreduced, Lane 6, endothelial cells were stimulated with :--JiCh ~g/ml of
heparin for 24 hours and were run nonreduced, Lane7, endothelial cells stimulated \Vith
l\iCh for 24 hours and were run under reducing conditions, Lane 8, endothelial cells
stimulated with PMA for 24 hours and were run under reducing conditions, Lane 9,
endothelial cells stimulated with NiCl2 and 200 ~g/ml of heparin for 24 hours and run
under reducing conditions, and Lanes 10-14, secondary antibody controls.
Figure 5.6: An Attempt to Probe for ICAM-t
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Immunoblot o(IC\\I-; SDS-P:\(iL \\as runllfcell-surtilCe proteins as
described in Chapter -\. the experimentatil)n section Electrophoresis \"'~b carried ,Jut in
Sf) I) plllvacf\ lamide gel and prllbed for Ie0\\1-1 \\ ith commercially available antiblJdy
The samples applied \\ere Lane I. rainbow molecular weight marker, Lane 2.
hiotil1\ lated molecular \\ eight marker. Lanes 3. 0 hour controls. no stimulation of
cnd\)[heli,ll celb. Lane -\. endothelial cells were stimulated v"ith i\iCI, for 2-\ hours and
were run ll11nreduced. l.ane~ :'. endllthelial cells \\ere stimulated with P\IO\ for 2.+ Iwurs
,1I1d ,-,ere run nonreduced. l.aneh. endothelial cells were stimulated \\ ilh '\JiCI: ~lgl1ll \11'
heparin lor 2.+ hllurs and were run l1onreduced. l.ane7. endothelial cells stimulated with
"iC:: I~)f 2-\ h\)urs and \\ere run under reducing conditions. Lane S. endothelial celb
stimulated \\ith PMO\ tor 2-\ hours and \\ere run under reducing cllnditillns. I.ane 'l.
end\)! helial cells stimulated with i\iCI: and 200 flgJ11lll)f heparin I'm 2-\ l1\1urs and nUl
under reducing Cllnditillns. and I.Jnes 10-1'+, ~econdary antibodv controls
Figure S.6: An Attempt to Probe for IC:\.\I- t
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X-ray lilm ut' Thrombospondin and Fibront:ctin SDS-Pi\GE was run ut' ceil-
3urtace proteins as described in Chaptcr 4. the expcrimcntation 3CCtlOn
F\ectrophoresis was carried out in i 0% reducing poiyacrylamide gel :lnd the
! :!uioil!l!Il11IlUplt:c!pilcliul1 ut' TSP wilh CUI1IJ!H,;'I ciall: available 1!lIlibmJy \vc~
Lmes (\.~ '.and tiL and radioimmunoprecipitation of fn "",ith commercially
available antibody \Vas Lanes (3 and!) The samples applied were Lane!.
untreated endothelial cells. Lane 2. endothelial cells treated with! 00 ~lg!m! of
heparin for 24 h,,'urs. Lane 3. untreated endl1!helial cells, Lane 4, enduthelial (e!1s
treated wit.h IflO !.lgJllll of heparin for 24 hour", Lane 'i. untreated endothelia!
l~ells, and I.ane A endothelial cells treilled \vith 100 pg/ml nfhepilrin I,)r 24
hours
Figure 5.i: Fihronectin and Thrombospondin Cell Associated Proteins
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\:-r,l)' film uf Fibrunectin and Thrumbospondin proteins released into the media. SDS-
I'-\(IL was run of proteins released into the media as described in Chapter 4. the
c'\pe;irnentation section Electrophoresis was carried out in 10% reducing poly?cryial11ide
gt:! anu the I aJioiIllIllUIIOPIt'L:ipitaliofl 01" Fl\ wilh L:oIJll!le!L:ially available aIlliboJy wa~
I <lilt'S ( 1.2. S. and 6), and radioimmunoprecipitation ofTSP with commercially available
antibody was Lane~; (3.'1. 7 and 3). The samples applied \vere: Lanes U. 5 and 7
'.lntrc,lted media ofendothelia! cells. and Lanes 2.4. 6. and 8. media of endothelial cells
tr,:ated \\!th 100 ~lg/ml of heparin for 2..l hours.
Figure 5.8: Fibronectin and Thrombospondin Proteins Released into the
Media
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X-ray film of Fibronectin protein released into the media. SDS-PAGE was run of
proteins released into the media as described in Chapter 4. the experimentation section.
Electrophoresis was carried out in 10% reducing polyacrylamide gel and the radio-
irnmulluprecipilaliun uf FT" wa:; performed wilh curnrm:rcially available anlibudy.
The gamples applied were: Lane I, untreated media of endothelial cells. Lane 2, media of
endothelial cells treated with 50 !lg/ml of heparin for 24 hours, Lane 3, media of
endothelial cells treated with 100 Ilglm\ of heparin for 24 hours. and Lane 4. media of
endothelial cells treated with 200 Ilg/ml of heparin for 2t1 hours.
Figure 5.10: Fibronectin Proteins Released into the Media
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\-:',1\' ri:m uf Fibruncetin prlltcin rt:lcased irltl) thc l11cdia SDS-P\GE \\as run llf
p;'()teii1~ r'eleased into the media as descnbed in l'i1apter -t, the e'\penmentatllln sectilln
L':ectwphoresis \\ as earned out in 11)° 0 reducing puhacr\lamide gel and the radiu-
iJllrllullllpll:ciiJilaliun ,liTi\ \\a~ ~'eJll)fjneJ wilh cOlflfllclcially a\.aiiabie anlibudy
The samples applied \lere I.ane I. untreated media lif endothelial cells, Lane~. media "I'
dldl1lhclial cells treated "ith -,:) pg/ml of heparin t'ur ~-t hours. l.ane 3. ilicdia of
cnd,1thelial cells treated with \00 ~lgim\ of heparin lor 2-t hours, and Lane .f, media ,)f
cndl1thelial (ells :rc:lted \\ ith .20() fl,g, m) of heparin lor .2 I huurs
Figu re 5. to: Fibronectin Proteins Released into the Media
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Immunoblot of Fibronectin. SDS-PAGE \vas run of cell-surface proteins as described in
Chapter 4, the experimentation section. electrophoresis \vas carried out in IU~/O reducing
polyacrylamide gel and probed for Fibronectin with commercialiy available antibody The
salllpks app/ieu were. Lane I. rainbuw lIlulet:ular weighL marker. Lane 2, unLn:aLeu
\:'ndllthe1ia\ cells, Lane ~ endothelial cells treated with 50 ~lg/ml of heparin for 24 hours,
Lane 4 endothelial cells treated with 100 pg/ml nfheparin for 24 hours, and Lane 5,
endothelial cells treated -"",ith 200 ~lg/m\ of heparin for 24 hours
Figure 5.1 t: Fibronectin Cell Associated Proteins
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Ll1ll1l1l11lhl,)l'li'l,hi"ll1t:Clin SDS-P·\(jF \\,IS rlll1l1l'(l'l:-,urt~1CeiJr,neil1s as dcscnhdn
l haptc,' -I. t!lC c'pertmCI11alil1n SCC:IO[1 l.lccli"Op!1Un:sh \\as camed ,JUIII1 11)°,) n:dlil:;"~
p"'''Icr,lat'lllk ~cl :md ;m~bcd j()r hbronccl:n \Iith commcrcial!\ :l\:1ii:lh\C :lI1libu,h' TilC
',!1"P:<:~ dppi!L"J IIl'lC l.alle I. Iil!lIbu\1 lJIu1ecuiJI lIL"i)!!Jl !lIdl;"L"!. l.:ule =, U1!lle,lleJ
,'I,d"l h'kl\ ll::;S. \ MIL" , end,,! heliai c,'\b II ,'akd ,\;; h :'1) \l~ Ini "i' hq)(t\in \'(lr =-1 hllUh
I dlh: 4 ,,\jjdotlk'lia! (L'lb trcah:\d \~irh 1(;0 p~'-nlll·,r:lt:parin f~H· :41hllii',"" dild Lcijj('':;
L'lj(~\)~h~lial ~c;L") treated \\llh ::-H) p~'1ill \~d'hLparin f()f :4 hi..'llr~
Figure 5. t t: Fibronectin Cdl Associated Proteins
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Immunoblot of Fibronectin and Laminin proteins released into the media.
Immunoprecipitation of proteins released into the media was perromled as described in
Chapter 4, the experimentation section. SDS-PAGE was run of proteins released into the
media. Electrophoresis was camed out in 8% reducing polyacrylamide gel and probed for
Fibronectin, Lanes (3-6), and Laminin, Lanes (7-10) with commercially available antibody
The samples applied were Lane I, rainbow molecular weight marker, Lane 2,
biotinylated molecular weight marker, Lanes 3, and 7, untreated media of endothelial cells,
Lanes 4, and 8, media ofendothelial cells treated with 50 ~lg/ml ofhepann for 24 hours,
Lanes 5 and 9, media of endothelial cells treated with 100 Jlglml of heparin for 24 hours,
Lanes 6 and 10, media of endothelial cells treated with 200 flg/ml of heparin for 24 hours,
and Lane 11, secondary antibody control.
Figure 5.12: Fibronectin and Laminin Proteins Released into the
:\1edia
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LliIllunoblot of libronectin and Lllnlnin pmteins I'eleased into the media
1:11lnurwprecipitatil)J1 \)l'pI\)teins released into the media \VdS pelilmlled as described ill
Clapter -t lhe e\perimentatilln section SDS-P-\GE I\as wn or proteins released inlO :1Ie
media Lk:cliophl1lesis I\~b carried l)ul in SO 0 reducin~ Pl)IVdCf\I,lll1lde gel and prnhed Il)r
libroneclin, l.anc~ (;-1,). and Laminin, l.anes (7_11')) \\-ith commerciallv a\ailable antibl,dv
The sampk~ ,lpplied Ivere Ldne I. rainblw. ml)iewlar \\-ei~ht marl,er, l.dne 2,
:'iol:m laled l1lolecular I\eight marker. Lanes -', and I, untreated media uf endothelial L'elk
I,mes ~, and S. media nf end\)theiial cells treated with 50 ~lg.mll)t' heparin fl)r 2~ hour,.
1,111\:5 -; and 9, media or endnthelial cells treated v,ith :00 pg.ml or heparin It,r 2-+ Ih 1urs,
1,1l1es iJ and 10, media nf endothelial cells treated with 2UO ~lg..ml nfhepdrin ll)r 2~ hlhllS,
,111\: 1,lnl: I 1, ~econdarv antiblldy cllntrl,l
Figure 5.12: Fibronectin and Laminin Proteins Released into the
:\Iedia
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FIGURE 5.13: FIBRONECTIN CELL ASSOCIATED PROTEIN
LEVELS AS A RESULT OF HEPARIN TREATMENT
AU Value vs. Micrograms of Heparin
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FIGURE 5.14: FIBRONECTIN PROTEIN RELEASED INTO THE
MEDIA AS A RESULT OF HEPARIN TREATMENT
AU Value vs. Micrograms of Heparin Added
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Immunoblot of Laminin. SDS-PAGE was run ofcell-surface proteins as describe in
Chapter 4, the experimentation section. Electrophoresis was carried out in 5% reducing
polyacrylamide gel and probed for Laminin with commercially available antibody. The
samples applied were: Lane 1, secondary antibody contrul, Lane 2, endothdial cells
treated with 200 ~g!ml of heparin for 24 hours Lane 3, endothelial cells treated with
100 ~g1ml of heparin for 24 hours, Lane 4, endothelial cells treated with 50 ~g1ml of
heparin for 24 hours, Lane 5, untreated endothelial cells, Lane 6, biotinylated molecular
weight marker, and Lane 7 rainbow molecular weight marker. '
Figure 5.19: Laminin Cell Associated Protein
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Iml11unoblot of Laminin. SDS-PAGE Vias run of cell-surface proteins as describe in
Chapter 4, the experimentation section. electrophoresis was carried out in 5% reducing
pl1iyacrylamide gel and probed !ix Laminin with commercially availahle antibody The
samples applied were: Lam: I, sel:Undary antibody controL LaIl\:: 2, endothelial cells
lrt'aled with 200 ~g)1l11 of heparin for 24 hours Lane 3. endothelial cells treated \~itlJ
100 llg/ml of heparin for 24 hours, Lane 4. endothelial cells treated with ,,0 ~g/ml of
heparin for 24 hours. Lane 5. untreated endothelial cells. Lane 6. biotinylated molecular
weight marker, and Lane 7 rainbow molecular weight marker.
Figure 5.19: Laminin Cell Associated Protein
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Irnmunoblot ofLaminin protein released into the media. lmmunoprecipitation ofLaminin
protein released into the media was performed according to Chapter 4, the
experimentation section with commercially available antibody. SDS-PAGE was run of
proteins released into the media. Electrophoresis was carried out in 5% reducing
polyacrylamide gel and probed for Larninin. The samples applied were: Lane 1,
secondary antibody control, Lane 2, media of endothelial cells treated with 200 l!g/ml of
heparin for 24 hours, Lane 3, media ofendothelial cells treated with 100 ~m1 ofheparin
for 24 hours, Lane 4, media ofendothelial cells treated with SO l!g/m1 of heparin for 24
hours, and Lane 5, media ofuntreated endothelial cells.
Figure 5.20: Laminin Protein Released into the Media
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Immunoblot of Laminin. SDS-PAGE was run ofcell-surface proteins as described in
Chapter 4, the experimentation section. Electrophoresis was carried out in 6% reducing
polyacrylamide gel and probed for Laminin with commercially available antibody. The
samples applied were: Lane 1, rainbow molecular wdghl marker, Lane 2, biolinylaled
molecular weight marker, Lane 3, untreated endothelial cells, Lane 4, endothelial cells
treated with 50 /lg/ml of heparin for 24 hours, Lane 5, endothelial cells treated with
100 /lg/ml of heparin for 24 hours, Lane 6, endothelial cells treated with 200 /lg/ml
of heparin for 24 hours, and Lane 7, secondary antibody control.
Figure 5.21: Laminin Cell-Associated Protein
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X-ray film of Laminin. Radioimmunoprecipitation of Laminin cell-associated
protein was performed according to Chapter 4, the experimentation section with
commercially available antibody. SDS-PAGE was run ofcell-associated protein.
Electrophoresis was carried out in 5% reduc.ing polyacrylamide gel. The samples
applied were: Lane 1, untreated endothelial cells, Lane 2, endothelial cells
treated with 50 Ilglm1 of heparin for 24 hours, and Lane 3, endothelial cells
treated with 200 Ilg/ml of heparin for 24 hours.
Figure 5.22: Laminin Cell Associated Protein
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FIGURE 5.24: LAMININ CELL ASSOCIATED PROTEIN LEVELS AS
RESULT OF HEPARIN TREATMENT
AU Value vs Micrograms of Heparin
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X-ray film of Laminin. Radioimmunoprecipitation of Laminin cell-associated protein and
protein released into the media was performed according to Chapter 4, the
experimentation section with commercially available antibody SDS-PAGE was run of
cell-associateu protein anu protein releaseu into the meuia. Electruphoresis was carrit:u
out in 5% reducing polyacrylamide gel. The samples applied were: I,ane, 1 untreated
endothelial cells Lane, 2 endothelial cells treated with SO Ilg/ml of heparin for 24 hours,
Lane 3, endothelial cells treated with 100 llg/m1 of heparin for 24 hours, Lane 4
endothelial cells treated with 200 Ilglml of heparin for 24 hours, Lane 5, untreated media
of endothelial cells, Lane 6 media of endothelial cells treated with SO ~lg/ml of heparin
for 24 hours, Lane 7 media of endothelial cells treated with 100 Ilgfml of heparin for
24 hours, and Lane 8 media of endothelial cells treated with 200 Ilg/ml of heparin for
24 hours.
Figure 5.26: Laminin Cell Associated Protein and Protein Released
into the Media
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Figure 5.26: Laminin Cell Associated Protein and Protein Released
into the J\ledia
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Figure S.27: l.aminin Ceil Associated Protein
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[mrnunoblot of Laminin. SDS-PAGE was run ofcell-surface proteins as describe in
Chapter 4, the experimentation section. Electrophoresis was carried out in 5% reducing
polyacrylamide gel and probed for Laminin with commercially available antibody. The
samples applied were: Lane 1, untreated endothelial cells, Lane 2, endothelial cells treated
with 200 IJ.g/ml of heparin , Lane 3, endothelial cells treated with cycloheximide, Lane 4,
endothelial cells treated with cycloheximide and 200 llglml heparin, and Lane 5, secondary
antibody control.
Figure 5.28: Laminin Cell Associated Protein
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Immunoblot of Laminin. SDS-PAGE was run of cell-surface proteins as describe in
Chapter 4, the experimentation section. Electrophoresis was carried out in 5% reducing
polyacrylamide gel and probed tor Laminin with commercially available antibody The
samples applied ""ere: Lane I, untreated endothelial cells, Lane 2, endothelial cells treated
""ith 200 Fg/1ll1 of heparin, Lane 3, endothelial cells treated with cycloheximide, J,ane 4 ,
endothelial cells treated with cycloheximide and 200 ~lglml heparin, and Lane 5, secondary
antibody control.
Figure 5.28: Laminin Cell Associated Protein
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Chapter 6: CONCLUSION
During the initial stages of atherosclerosis, the integrity of the vessel wall is
compromised. The endothelium is damaged resulting in the attachment of monocytes
and the destruction of the extracellular matrix. Since heparin has been observed to
reverse atherosclerotic effects, it is important to study the effect of heparin on
extracellular matrix glycoproteins and cell adhesion protein levels.
To study the cell-adhesion molecules P-selectin and ICAM-l, activation was
required. Unfortunately, it was difficult to obtain data. It is hard to believe that
activation of the endothelial cells did not take place since three different activators were
applied to study both proteins according to information published in the literature,
however, activation may not have occurred. The problem may lie in the antibody
recognition since the antibody was developed in human cells and work was performed on
porcine endothelial cells. In addition, according to Bonfanti, et. aI., (1989) P-selectin can
be localized to the Weibel Palade bodies ofhuman umbilical vein endothelial cells by
immunofluorescence regardless of whether or not activation has occurred. However,
when immunofluorescence was performed on porcine cells, no fluorescence was
observed on either activated or unactivated cells.
Speculation as to what should have been observed by the addition of heparin, one
should see a decrease in both P-selectin and ICAM-l protein levels possibly by slowing
or reducing the synthesis of these two molecules with the addition of heparin working
through its receptor. In theory, if heparin is discussed as a possible treatment for
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atherosclerosis and P-selectin and IeAM-I are involved in the initial stages ofvessel
injury, therefore, through its receptor, heparin will increase the electronegativity of the
endothelium which should result in decreased protein levels of these two molecules.
The extracellular matrix glycoproteins, fibronectin, thrombospondin, and laminin
were then studied. These glycoproteins are involved in adhesion, also. With the addition
of heparin, fibronectin protein levels increased at both the cell-surface and the proteins
released into the media. To study the protein levels at the cell surface, immunoblots
were performed to determine the change in newly synthesized protein and expressed
protein levels while radioimmunoprecipitations were also performed which analyze only
newly synthesized protein. For both experiments, heparin treatment resulted in an
increase in fibronectin protein levels. When the media from these cells was analyzed by
immunoprecipitation and radioimmunoprecipitations, the fibronectin protein released
into the media also showed increased protein levels. The difference between the heparin
treated lanes and untreated lanes was statistically significant as determined by regression
analysis (a = 0.05).
In addition, when these result were compared to Lyons-Giordano et. al. (1990),
the results appeared similar to the published information when endothelial cell growth
factor was not added. However, according to Lyons-Giordano et. al. (1'990), when
growth factor was added to the culture medium, fibronectin protein levels decreased with
heparin treatment. If growth factors were added to our culture medium, it would be
difficult to ascertain whether the change in protein levels was occurring from the growth
79
factors or heparin alone since growth factors are known to work through receptors and
cause changes in the proliferation of endothelial cells.
Fibronectin protein levels may be increasing in the presence of heparin treatment
in part because of its functional role in spreading and migration.
Thrombospondin was the next extracellular matrix glycoprotein studied. Because
of the high molecular weight of the thrombospondin protein, 450 kDa, transfer to
nitrocellulose would be difficult using the immunoblot technique, therefore, only
radioimmunoprecipitations were performed to study heparin's effect on newly
synthesized protein levels. Thrombospondin protein levels decreased at both the cell-
surface and in the media with the addition of heparin treatment, which also compares
similarly to the Lyons-Giordano article. The difference observed between the heparin
treated lanes and the untreated lanes was also statistically significant using regression
analysis (a = 0.05). Thrombospondin's main function is in angiogenesis, however, it can
also serve as an adhesive and anti-adhesive molecule. Therefore, because of its
functional role as an anti-adhesive molecule, it may in part explain why protein levels are
decreasing.
The last extracellular matrix glycoprotein studied was laminin. When heparin
treatment was applied to endothelial cells, laminin protein levels were affected at the
cell-surface. Protein levels sometimes increased using one endothelial cell line and
sometimes decreased using another cell line at the cell surface for the 400 kDa A chain
and also for the B1,B2 chains which usually migrate as a single protein band. Variability
occurred between endothelial cell lines but did not occur within a particular cell line.
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Laminin protein levels were not affected by confluency of cell cultures or passage
numbers. In addition, changes in lots of serum or heparin did not affect laminin protein
levels since heparin induced increases in protein levels occurred one week while
decreases in laminin protein levels using a different cell line occurred the following
week.
When cycloheximide and heparin were applied, both induced changes of newly
synthesized laminin protein levels at the cell surface by the observed reduction in the 400
and 200 kDa subunits. An attempt to study the laminin mRNA expression pattern when
heparin treatment was applied was unsuccessful and therefore no information could be
obtained. The cDNA that was obtained may not have been exactly complementary to the
B1 region of porcine laminin since the probe was developed complementary to the B1
region of human laminin. In addition, according to Webersinke, et. al. (1992), the
laminin B1 may not have been detected because of an extremely rapid turnover of
laminin B in the cell due to the presence of a destabilizing 3' untranslated region in the
laminin B message.
When immunoblots were performed on the laminin protein released into the
media, newly synthesized and expressed laminin protein levels of the 200 kDa subunit
remained the same regardless of whether or not heparin treatment was applied. The 400
kDa subunit did not appear on the immunoblots and results cannot be compared to the
radioimmunoprecipitation data for this same subunit. Consistent with our results, it has
been observed in astrocytes, Schwann cells, and schwannomas that these cells produce
and release the B chains, but not the 400 kDa, A isoform oflaminin (Chiu, et. al., 1991).
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Also, in skeletal muscle it has been observed that the B chains are always expressed but
the levels of the A chains are low and often undetectable. It is becoming increasingly
clear that the chain composition of laminin varies from tissue to tissue and, even within a
particular tissue, as a function of development (Boot-Handford et. aI., 1987).
When radioimmunoprecipitations were performed on the laminin protein released
into the media after the addition of heparin treatment, newly synthesized 400 kDa A
chain increased while the newly synthesized 200 kDa, B1,B2 chain decreased. The 400
kDa subunit may be controlling the availability ofthe amount of the 200 kDa subunit that
is synthesized in this case. When cycloheximide was applied, laminin protein released
into the media was unaffected.
Changes in laminin protein levels, after heparin treatment was applied, could be
due to variability between endothelial cell lines, but not within a particular cell line since
similar results were obtained from the same cell line, regardless ofpassage number or
confluency of the endothelial cell line. Vanability in the results at the cell surface may
be due to low levels of smooth muscle cell contamination of the cell line which was
undetectable at the time the experiments were carried out. While low levels of
contamination may not have an effect on fibronectin or thrombospondin, laminin might
be affected by it.
In addition, as stated above, the 400 kDa subunit may not have appeared due to
the possibility that during development and differentiation of the matrix of the cell line,
expression of this isoform was not detected by the polyclonal Ab commercially
purchased for these experiments. Unless particular isoforms for laminin are obtained, it
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is difficult to determine what results would have been obtained. When regression
analysis was run for laminin, heparin induced changes were found to be statistically
significant for the changes observed for both subunits (a = 0.050).
Finally, the information presented here demonstrates that heparin's effect on
endothelial cell growth and protein biosynthesis may be particularly important in the
repair ofthe vessel wall following injury, an early step in the development of vascular
disease particularly atherosclerosis. Therefore, an understanding of heparin's action on
the endothelial cells and these molecules may eventually provide clues to restoring vessel
wall integrity in diseased states.
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Appendix A
Buffers and Solutions for Protein and Antibody \Vork.
**Unless otherwise noted all solutions in this appendix are made with 18 M ohm/em
water, are 0.2 Jun filtered and can be stored at room temperature.
Alkaline }JllOsphafe H14jer, pH 9.5
-This butTer can be made as a lOX stock solution.
Components
Tris-Base, 100 mM
NaCI, 100 mM
MgCI 2 6H20, 5 mM
amount/liter
12.12 g
5.84 g
1.0lg
To make working solution add 50 pi ofNBT and 25 J1l ofBCID to 25 ml of IX
butfer.
HCIF Stock
-not 0.2 Jon filtered
-stored at - 20° C
Components
-50 mg SCIP; 1.0 ml of water
87
iVR r .'<1 lick
-stored at - 20' C
l'umponents
50 mg NBT/ 1.0 ml of70% DMF
J)!:SJAIN 1
Components
Methanol 50%
Acetic Acid 10%
Glycerol 2%
Fho,'phale Hujj'ered Saline (PH::'). pH 7.-1
-This buffer can be made lOx as a stock solution.
Components
KCL,2.7mM
KH2P04, 147 mM
NaCI, 137 mM
Na2HP04, 8.2 mM
Flw.'plwle Huj.fCred Saline and 1% CHAPS
Components
88
amount/I iter
500.00 mL
100.00 mL
20.00 mL
amount!l iter
0.2 g
0.2 g
8.0 g
1.15 g
amount/liter
PBS Ix
CHAPS. 1.0%
molio
1000 mL
10.0 g
-This solution is heated to 10° C for one hour when tirst made to fully dissolve all
the milk protein.
-Stored at 4' C and is not tiltered
Components
Non-fat Dry Milk, 5%
NaN] 6 mM
Bovine-Serum Albrimin, 3%
lOx Tris Buffered Saline-TBS, 10% (See Below)
l'ris Buffered Saline (1'8S), pH 7.5
-This buffer can be made lOx as a stock solution.
Components
Tris-Base, 50 mM
NaCI, 150 mM
f'ris Buffered Saline and 0.1% Tween-20 (l'HSl)
-This butTer can be made lOx as a stock sol ution.
Components
89
amount/liter
50.0 g
0.4 g
30.0 g
100.0 mL
amount/liter
6.06 g
8.77 g
amount/liter
TBS,lx
Components
Tris-Base, 12.5% mM
Glycine, 96 mM
Hromophenul Hlue
Components
Bromophenol Blue, 0.1 %
Phosphate-Citrate Hu;Uer, pH 5.0
Components
0.2 M Dibasic Sodium Phosphate
0.1 M Citric Acid
1000 mL
I.U g
amount Iiter
1.5 g
7.2 g
amounvliter
1.0 g
amount/liter
257 mL
243 mL
To make working buffer, add 10 tablets of ABTS in IL of this buffer, then add 250
mL of 50% H20 2 (male working buffer fresh)
lJ,hasic Sodium Phosphate
Components
Na2HP04, 0.2 M
90
amount/liter
28.4 g
Citric Acid
Components
Citric Acid, O. I M
91
amount/liter
19.2 g
,\ppendix B
Buffers and Solutions for Laemmli Style 50S-GEL Electrophoresis
**All solutions \\-ere prepared with 18 M ohmcm water
('ummacwlly uvuill1hl<: AClylumide-fNs-Acrylatnide
.-ICl~vl(/mide .\/ock, 37.5: I - Acryl:H!S (Amru.l'co, .\·olon, CJH)
Acry·lamide,38.96%l
BIS - Acrylamide, 1.04%l
Resolving Gel Hz~frer, pH 8.8
Components
Tris-Base, 1.5 M
,~'tl1cking Gel Hz!f(er, pH 6.8
Components
Tris-Base, 0.5 M
,\'1J.",' Stock, 10%
Components
SOS,IO%
92
amount/l iter
181.5 g
amount/I iter
60.0 g
amount/I iter
100.0 g
Sump/!! Rulfer OX), pH 6H
Components
Tris-Base, 12.5 mM
SDS Stock, -l~'o
2-Mercaptoethanol, 15 mM
amounti 10m L
1.513 g
-l.00 mL
1.00 mL
(2-Mercaptoethanol may be excluded to make a non-reduced sample buffer)
lunk (Running) RuiTer, pH 8.3
Components
Tris-Base, 25 mM
Glycine, 192 mM
SDS-Stock, 0.4%
amountiliter
3.00 g
14.40 g
4.00 mL
Recipe jiir Standard Gel (15 em x 15 em x 1.5 mm - 10% Separating; -1% Slacking)
Separating Gel amount/gel
Acryamide Stock 7.5 mls
Separating Gel 7.5 mls
Stock SDS 0.3 mls
Water 14.5 mls
Ammonium Persulfate* 150J.11
TEMED* 10J.11
93
Stacking Gel
ACI)'lamide Stock
Stacking Gel Buffer
Stock SOS
Water
Ammonium Persulfate*
TEMEO*
1.3 mls
2.5 mls
0.1 mls
6.1 mls
50,u1
5It!
For polymerization a solution of 0.1 g Ammonium Persulfate per 1 ml of
water was made.
*Added to the degassed gel mix immediately before casting.
For a recipe of 8% separating gel substitute 6.0 ml of acrylamide stock and
]6.0 mls of water
For a recipe of 6% separating gel substitute 4.5 mls of acrylamide stock and
]7.5 mls of water
For a recipe of a 5% separating gel substitute 3.75 mls of acrylamide stock
and 18.25 mls of water
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Appendix C
Buffers and Solutions for R1\A \Vork
**All solutions in this appendix are made with DEPC-treated water.
lOX A./OFS Huffer /3-(N-morpholmo)-propanesu!jimic acid/ pH7. 0
-Filtered using Whatman #1 filter paper.
Components
MOPS
3M DEPC-treated Sodium acetate
0.5M DEPC-treated EOTA, ph8
Sodium acetate, pH 5.2
Components
CH-,COONa3H20, 3M
U)7'A, O.5M pH8.0 (ethylenediamine tetraacetic acid)
Components
NaJ::DTA2H20
95
amount/liter
41.8g
16.6 ml
20.0 ml
amount/liter
408.0 g
amount/liter
186.1 g
Components
agaro~c
lOX :'vIOPS, 10o~
I:(}rmalddlyde loading hufler
Components
Bromophenol blue, 0.25%
Xylene Cyanol, 0.25%
Glycerol, 50%
sse, pH7.0
-This buffer can be made 5X, lOX, and 20X as a stock solution.
Components
NaCl,150mM
96
aml)unt.liter
10,0 g
150.U tnl
100.0 tnl
amount.liter
0.375 g
2.5 g
500.0 ml
amount'liter
8.75 g
4.4 g
JJrc-hyhridt::at if III SfJ/ur ion
Com ponents
5X SSC (see above)
5X Denhardfs solution (see below)
Salmon sperm DNA, Smg/ml
Fom1amide, 50%
/'"j
amount/liter
25.0 ml
250.0 ml
50.0 ml
10.0 ml
500.0 ml
To make 30.0 ml of Northern hybridization solution, add 150 J-ll t-RNA baker's yeast
and cDNA probe (1 mg/ml)
!.ecfin Hlock
-Solution is heated to 65 0 C for one hour when first made to fully dissolve the
components.
-Store at 40 C.
-Not filtered.
Components
Cold Water Fish Gelatin, 1%
PVP, 1%
Tween-20, 0.1 %
lOX Tris Buffered Saline-TBS (see above), 10%
97
amount/liter
10.0 g
10.0 g
l.0 g
l.0 g
100.0 ml
I)en!zardf solution
This solution can be made IOOX as a stock solution.
Filtered using a Whatman # I filter paper.
Store at -20 0 ( ..
Components
Ficol1400
Polyvinylpyrrolidone
Bovine Serum Albumin
o. IiYf Tris' CI_, pH 7.5
Components
Tris-Base
NuCl-NaOH Buffer
Components
NaOH,50mM
NaCI,IOmM
98
amount/I iter
0.2 g
0.2 g
0.2 g
amount/liter
12.1 g
amount/liter
2.0g
0.584 g
rUF Hu!kr, I'rls-Howle-U)JA, pH H.3
This buffer can be made lOX as a stock solution.
Components
Tris-base,89mM
Boric acid, 89mM
EOTA-Free Acid, 2.5mM
99
amount/liter
10.8 g
5.5 g
0.74 g





